EGFR and non-small cell lung carcinoma: In recent years, randomized trials have further shown that patients with NSCLC harboring susceptible EGFR mutations, such as the exon 21 L858R point mutation and exon 19 deletion, have longer progression-free survival (PFS) when they are treated with EGFR TKIs rather than standard chemotherapy [10,11,12,13,14,15,16].